iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Stock Information for iBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iBio Inc.

iBio Reports Fiscal Third Quarter 2025 Financial Results
iBio Raises $6.2 Million Through Warrant Inducement Transaction
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
iBio to Begin Trading on the Nasdaq Stock Exchange
iBio Reports Fiscal Second Quarter 2025 Financial Results
iBio Announces New Investments from Board Members and Officers
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.